Free Trial

Supernus Pharmaceuticals (SUPN) Competitors

Supernus Pharmaceuticals logo
$33.87 +0.42 (+1.25%)
As of 02:42 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

SUPN vs. JAZZ, PRGO, PCRX, NKTR, OMER, ASMB, CPIX, LLY, JNJ, and ABBV

Should you be buying Supernus Pharmaceuticals stock or one of its competitors? The main competitors of Supernus Pharmaceuticals include Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), and AbbVie (ABBV). These companies are all part of the "pharmaceuticals" industry.

Supernus Pharmaceuticals vs. Its Competitors

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Jazz Pharmaceuticals currently has a consensus target price of $181.64, suggesting a potential upside of 56.45%. Supernus Pharmaceuticals has a consensus target price of $39.00, suggesting a potential upside of 15.15%. Given Jazz Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Jazz Pharmaceuticals is more favorable than Supernus Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jazz Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.93
Supernus Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 4.3% of Jazz Pharmaceuticals shares are held by insiders. Comparatively, 8.8% of Supernus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Jazz Pharmaceuticals has a net margin of 11.86% compared to Supernus Pharmaceuticals' net margin of 9.27%. Jazz Pharmaceuticals' return on equity of 26.62% beat Supernus Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Jazz Pharmaceuticals11.86% 26.62% 9.14%
Supernus Pharmaceuticals 9.27%12.23%9.17%

Jazz Pharmaceuticals has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.

Jazz Pharmaceuticals has higher revenue and earnings than Supernus Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jazz Pharmaceuticals$4.06B1.73$560.12M$7.5015.48
Supernus Pharmaceuticals$661.82M2.87$73.86M$1.1130.51

In the previous week, Jazz Pharmaceuticals and Jazz Pharmaceuticals both had 9 articles in the media. Jazz Pharmaceuticals' average media sentiment score of 1.10 beat Supernus Pharmaceuticals' score of 1.06 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Jazz Pharmaceuticals
6 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Supernus Pharmaceuticals
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Jazz Pharmaceuticals beats Supernus Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Get Supernus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SUPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SUPN vs. The Competition

MetricSupernus PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.89B$3.89B$5.61B$9.56B
Dividend YieldN/A1.17%4.71%4.03%
P/E Ratio30.497.5127.9020.10
Price / Sales2.8712.14392.4667.55
Price / Cash8.016.4836.3258.75
Price / Book1.812.798.395.83
Net Income$73.86M-$109.62M$3.25B$259.10M
7 Day Performance2.73%-0.62%-1.61%-2.35%
1 Month Performance7.45%10.03%9.08%9.75%
1 Year Performance11.85%23.40%35.49%17.02%

Supernus Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SUPN
Supernus Pharmaceuticals
2.585 of 5 stars
$33.87
+1.3%
$39.00
+15.1%
+9.3%$1.89B$661.82M30.49580News Coverage
Positive News
Upcoming Earnings
Analyst Upgrade
Gap Up
JAZZ
Jazz Pharmaceuticals
4.8181 of 5 stars
$112.65
-0.2%
$181.71
+61.3%
+4.9%$6.83B$4.07B6.712,800Positive News
Upcoming Earnings
PRGO
Perrigo
4.5303 of 5 stars
$26.91
-0.2%
$33.00
+22.6%
+0.4%$3.71B$4.37B9.398,379Upcoming Earnings
PCRX
Pacira BioSciences
3.2513 of 5 stars
$22.17
+2.7%
$26.44
+19.3%
+6.2%$999.42M$700.97M-9.72720
NKTR
Nektar Therapeutics
4.0778 of 5 stars
$24.79
-0.6%
$88.33
+256.3%
+12.3%$309.43M$98.43M0.00220News Coverage
Positive News
Upcoming Earnings
OMER
Omeros
3.7698 of 5 stars
$3.64
+8.3%
$18.00
+394.5%
-26.2%$196.87MN/A0.00210Positive News
Upcoming Earnings
ASMB
Assembly Biosciences
3.7987 of 5 stars
$18.25
-2.3%
$33.00
+80.8%
+26.4%$142.67M$28.52M-2.93100Upcoming Earnings
CPIX
Cumberland Pharmaceuticals
0.8895 of 5 stars
$3.50
+8.7%
N/A+144.1%$48.17M$37.87M-14.0080Upcoming Earnings
LLY
Eli Lilly and Company
4.9843 of 5 stars
$762.22
-1.2%
$1,012.56
+32.8%
-5.5%$731.38B$45.04B56.0847,000Trending News
JNJ
Johnson & Johnson
4.8287 of 5 stars
$164.38
+0.4%
$172.87
+5.2%
+6.0%$393.87B$88.82B16.37138,100Positive News
Analyst Revision
ABBV
AbbVie
4.5691 of 5 stars
$184.77
-2.4%
$211.29
+14.4%
+5.1%$334.31B$56.33B78.6255,000Trending News
Upcoming Earnings

Related Companies and Tools


This page (NASDAQ:SUPN) was last updated on 7/30/2025 by MarketBeat.com Staff
From Our Partners